Therefore, upregulation of TLRs by an atherogenic favoring lipid profile, and the resultant production of inflammatory cytokines via the NLRP3 inflammasome, is an important link between atherogenic dyslipidemia and the development of CVD in NAFLD patients [83]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.